248 related articles for article (PubMed ID: 33916930)
1. Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in
Li Q; Ma L; Qiu B; Wen Y; Liang W; Hu W; Chen N; Zhang T; Xu S; Chen L; Guo M; Zhao Y; Liu S; Guo J; Wang J; Wang S; Wang X; Pang Q; Long H; Liu H
Curr Oncol; 2021 Apr; 28(2):1424-1436. PubMed ID: 33916930
[TBL] [Abstract][Full Text] [Related]
2. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
3. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
[TBL] [Abstract][Full Text] [Related]
4. [Selection of postoperative adjuvant therapy for patients with stage IB lung adenocarcinoma: analysis of 653 cases].
Shen L; Chen Y; Yun T; Guo J; Liu X; Zhang T; Liang C; Liu Y
Nan Fang Yi Ke Da Xue Xue Bao; 2024 May; 44(5):989-997. PubMed ID: 38862458
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.
Wang S; Xie T; Hao X; Wang Y; Hu X; Wang L; Li Y; Li J; Xing P
Thorac Cancer; 2021 Oct; 12(19):2585-2593. PubMed ID: 34490724
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Adjuvant First-Generation TKIs versus Chemotherapy in Patients with Completely Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis.
Shen B; Wu D; Liu J; Yang Y
Cancer Invest; 2024 Jan; 42(1):63-74. PubMed ID: 38224061
[TBL] [Abstract][Full Text] [Related]
8. Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations.
Zhang G; Cheng R; Niu Y; Wang H; Yan X; Zhang M; Zhang X; Yang J; Wei C; Ma Z
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):651-657. PubMed ID: 36172729
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
[TBL] [Abstract][Full Text] [Related]
10. Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study.
Zhou J; Qin H; Miao J; Liu R; Wang W
Medicine (Baltimore); 2023 Jun; 102(26):e34110. PubMed ID: 37390279
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
12. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.
Hu F; Li C; Xu J; Guo J; Shen Y; Nie W; Zheng X; Wang L; Zhang H; Han B; Zhang X
Lung Cancer; 2019 Sep; 135():138-144. PubMed ID: 31446986
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study.
Wang Y; Yu W; Shi J; Qiu R; Jiang N; Wang Z; Yang J; Jia Z; Song M
Technol Cancer Res Treat; 2022; 21():15330338221100358. PubMed ID: 35607295
[No Abstract] [Full Text] [Related]
14. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma.
Chen YY; Lin KH; Kuo YS; Tsai YM; Huang HK; Huang TW
World J Surg Oncol; 2023 Oct; 21(1):326. PubMed ID: 37833769
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
He P; Wang Y; Yang S; Yu S; Wang Z; Li J; Wang B; Hao X; Wang H; Hu X; Zhang X; Shi Y
Zhongguo Fei Ai Za Zhi; 2013 Oct; 16(10):529-34. PubMed ID: 24113006
[TBL] [Abstract][Full Text] [Related]
17. The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis.
Lin C; Hu F; Chu H; Ren P; Ma S; Wang J; Bai J; Han X; Ma S
Thorac Cancer; 2021 Apr; 12(7):1084-1095. PubMed ID: 33660941
[TBL] [Abstract][Full Text] [Related]
18. Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE).
Qian K; Chen QR; He M; Wang ZT; Liu Y; Liang HG; Su ZY; Cui YS; Liu LJ; Zhang Y
Invest New Drugs; 2023 Feb; 41(1):44-52. PubMed ID: 36355317
[TBL] [Abstract][Full Text] [Related]
19. Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy.
Shen CI; Huang HC; Chiang CL; Luo YH; Shiao TH; Chiu CH
Lung Cancer; 2019 Dec; 138():52-57. PubMed ID: 31634655
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
Chen Y; Wei J; Cai J; Liu A
BMC Cancer; 2019 Aug; 19(1):793. PubMed ID: 31399067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]